Human Microbiome - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The human microbiome market size is expected to grow from USD 1.05 billion in 2025 to USD 1.22 billion in 2026 and is forecast to reach USD 2.54 billion by 2031 at 15.9% CAGR over 2026-2031. This report is Segmented by Product (Drugs, Supplements, Diagnostic Tests, Other Products), Application (Therapeutics, Diagnostics), Disease Area (Gastrointestinal Disorder, Cancer, and More), End-User (Hospitals and Clinics, and More), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). Market Forecasts are Provided in Terms of Value (USD).

Global Human Microbiome Market Trends and Insights

Advancements in Next-Generation Sequencing Lowering Microbiome Analysis Costs

Real-time nanopore sequencing devices such as MinION and PromethION have cut per-sample costs by roughly 70%, enabling routine profiling that once required centralized laboratories. Portable platforms permit point-of-care analysis of gut microflora, accelerating diagnostic turnaround and supporting longitudinal monitoring. Full-length 16S rRNA workflows delivered by PacBio systems further increase taxonomic resolution needed for biomarker discovery. Sequencing expenditures are trending toward the USD 100 threshold, elevating the feasibility of incorporating microbiome checks into chronic-disease management pathways. Hospitals are already piloting regular microbial surveillance for inflammatory bowel disease patients, confirming the clinical relevance of affordable sequencing. Combined, these advances are widening the addressable base of the human microbiome market across both diagnostics and therapeutics.

Rising Venture Funding for Microbiome-Based Therapeutics

Dedicated venture funds and strategic corporate investors allotted record capital to the sector in 2025, catalyzing dozens of seed and Series A rounds in Europe, North America, and East Asia. European developers such as Abolis Biotechnologies secured EUR 35 million to scale biomanufacturing capacity, while public-private initiatives like CARB-X handed out multimillion-dollar grants targeting antimicrobial-resistance applications. Janssen’s Human Microbiome Institute cemented flexible partnership vehicles that enable start-ups to co-develop co-therapy assets with large-scale drug manufacturers. Pharma-microbiome alliances frequently include equity investments tied to predefined milestones, giving young companies funding certainty and mentor access. The resultant capital inflows shorten development timelines, drive talent acquisition, and speed regulatory submissions, reinforcing the upward momentum of the human microbiome market.

Lack of Standardization and Regulatory Guidelines

Microbiome therapeutics straddle medicinal-product and transplant regulations, generating policy ambiguity that slows cross-border trials and market launches. Divergent definitions of live biotherapeutic products across the FDA, EMA, and Japan’s PMDA complicate dossier preparation and compromise mutual-recognition ambitions. Analytical discord persists as laboratories deploy varied DNA-extraction, library-prep, and bioinformatics workflows, producing inconsistent readouts that dampen clinician trust. Upcoming European Union rules governing substances of human origin promise eventual harmonization but will not take full effect before 2026. Until global norms converge, companies must budget for region-specific validation studies, raising costs and delaying revenue capture in the human microbiome market.

Other drivers and restraints analyzed in the detailed report include:

• Expanding Applications in Personalized Medicine
• Expansion of Direct-to-Consumer Microbiome Testing
• GMP Scale-Up Challenges for Live Biotherapeutics

Segment Analysis

Supplements maintained a 39.35% revenue share in 2025, reflecting longstanding consumer adoption and streamlined regulatory routes. Drugs, however, are on track to register an 17.9% CAGR through 2031, buoyed by landmark approvals such as VOWST and REBYOTA, which showcase clinically proven benefits against recurrent C. difficile infections. Initial roll-out of VOWST generated USD 10.4 million in Q4 2023, validating commercial appetite and emboldening additional filings. Probiotic supplements face mounting scrutiny as authorities delineate dietary products from live biotherapeutic drugs, prompting manufacturers to invest in randomized controlled trials.

Diagnostic assays remain the smallest contributor but attract intensified investment as companion tests become essential for patient stratification in oncology and metabolic trials. Postbiotics and engineered bacterial strains represent emerging niches that may bridge nutraceutical and pharmaceutical spaces. The bifurcation of consumer-grade and prescription-grade offerings underpins diversified revenue streams within the broader human microbiome market.

Therapeutic use cases accounted for 69.35% of revenue in 2025, yet diagnostics enjoy a forecast 18.8% CAGR to 2031 as sequencing costs plummet and analytical software matures. Hospital networks are piloting stool-based panels that predict response to immuno-oncology agents, improving treatment selection and reimbursement outcomes. Fecal microbiota transplantation remains the archetypal therapeutic model, but pipeline assets now encompass oral capsules, topical formulations, and engineered strains targeting metabolic, autoimmune, and neurologic diseases.

The convergence of end-to-end platforms that combine sampling kits, sequencing services, AI analytics, and targeted interventions promises integrated care pathways. Developers able to link a validated diagnostic to a proprietary therapeutic could capture outsized value across the human microbiome market size.

Complete Report Scope:

• By Product
  • Drugs
  • Supplements
    • Probiotics
    • Prebiotics
    • Synbiotics
  • Diagnostic Tests
  • Other Products
• By Application
  • Therapeutics
  • Diagnostics
• By Disease Area
  • Gastrointestinal Disorders
  • Metabolic Disorders
  • Cancer
  • Autoimmune & Inflammatory Diseases
  • Central Nervous System Disorders
  • Other Applications
• By End-user
  • Hospitals and Clinics
  • Pharmaceutical & Biotechnology Companies
  • Research & Academic Institutes
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America commanded 41.75% of global revenue in 2025, underpinned by FDA guidance, seasoned venture networks, and a critical mass of GMP plants. Early adopter hospitals routinely implement fecal microbiota transplantation for recurrent C. difficile and are piloting diagnostic panels for oncology. Increasing reimbursement clarity supports broader uptake, solidifying the region’s influence on human microbiome market dynamics.

Europe benefits from dense academic clusters and coordinated funding frameworks; the European Commission’s 2025 biotechnology roadmap prioritizes microbial therapeutics for health and sustainability. Yet divergent national oversight regimes slow multicountry trials, keeping manufacturers reliant on expensive parallel submissions. Public-private partnerships such as those in France and the Netherlands supply translational funding that sustains competitiveness.

Asia-Pacific is projected to record an 18.35% CAGR as regulators converge on harmonized standards and local companies pour capital into fermentation and fill-finish capabilities. The JSR-Metagen plant scheduled for 2025 in Japan exemplifies the region’s resolve to nurture domestic production capacity. Partnerships like Zuellig Pharma’s decade-long deal to distribute OMNi-BiOTiC probiotics across Southeast Asia further enlarge the addressable base. China and South Korea expedite commercialization by bundling microbiome projects with national precision-medicine policies. Collectively, these developments broaden global participation in the human microbiome market.

List of Companies Covered in this Report:

• Seres Therapeutics Inc.
• International Flavors & Fragrances Inc. (IFF Health)
• OptiBiotix Health PLC
• Biomebank
• Pendulum
• Axial Biotherapeutics Inc.
• Finch Therapeutics Group
• 4D Pharma PLC
• Enterome SA
• Evelo Biosciences Inc.
• Microba Life Sciences Ltd.
• Osel
• Second Genome
• Vedanta Biosciences Inc.
• BiomX Inc.
• Synlogic
• Chr. Hansen Holding
• Probi AB
• Assembly Biosciences Inc.
• Kaleido Biosciences Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support